

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

**宜昌東陽光長江藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 01558)**

## **ANNOUNCEMENT POSITIVE PROFIT ALERT**

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company hereby informs the shareholders and potential investors of the Company that, based on the currently available unaudited management accounts of the Group and the preliminary assessment by the Company’s management, for the year ended 31 December 2022, the Group is expected to record net profit attributable to the parent company of approximately RMB68 million as compared to the net loss attributable to the parent company of approximately RMB588 million for the year ended 31 December 2021. The expected increase is primarily attributed to the facts that the footfall and daily social activities have gradually resumed to normal, and the traffic, diagnosis, treatment activities and the volume of prescriptions in frontline medical facilities have shown encouraging signs of recovery in China in 2022.

The Company is still in the process of finalizing its annual results announcement for the year ended 31 December 2022. The information set out in this announcement is only based on a preliminary assessment by the management of the Company based on the unaudited management accounts of the Group for the year ended 31 December 2022 and other information currently available to the Company, which has not been reviewed or audited by the Company’s auditors. Details of the financial information for the year ended 31 December 2022 of the Group will be disclosed in the annual results announcement of the Company, which is expected to be published on 24 March 2023.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**  
**TANG Xinfu**  
*Chairman*

Hubei, the PRC  
17 March 2023

*As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfu as a non-executive director; and Mr. TANG Jianxin, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive directors.*